Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
314 studies found for:    nash
Show Display Options
Rank Status Study
21 Completed Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance
Condition: NASH Related Cirrhosis
Interventions: Drug: Metformin;   Drug: Insulin
22 Recruiting Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH
Conditions: Obesity;   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease
Intervention: Behavioral: Comprehensive Lifestyle Intervention
23 Not yet recruiting Phase 2b Study in NASH to Assess IVA337
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: IVA337 1200mg;   Drug: IVA337 800mg;   Drug: Placebo
24 Unknown  Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
Condition: Obesity
Intervention: Drug: Metformin
25 Completed Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
26 Completed Omega 3 Supplementation in Fatty Liver
Condition: Fatty Liver
Intervention: Dietary Supplement: Omega 3
27 Recruiting Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Weight Loss;   Non-alcoholic Steatohepatitis (NASH)
Interventions: Behavioral: Lifestyle modification;   Drug: Liraglutide
28 Recruiting Open-Label Study To Evaluate Efficacy, Safety, Tolerability & PK of MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Conditions: Non-alcoholic Steatohepatitis;   Hypertriglyceridemia;   Non-alcoholic Fatty Liver Disease
Intervention: Drug: MN-001
29 Terminated Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
Condition: NASH (Non-alcoholic Steato-hepatitis)
Interventions: Drug: Rosiglitazone;   Drug: alpha-lipoic acid;   Drug: Rosiglitazone/alpha-lipoic acid
30 Recruiting Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-9674;   Drug: Placebo to match GS-9674
31 Active, not recruiting Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
32 Recruiting A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
Intervention:
33 Active, not recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
34 Completed Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GS-4997;   Biological: SIM
35 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
36 Recruiting A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
Condition: Fatty Liver
Intervention: Drug: Aramchol
37 Completed Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Pioglitazone;   Drug: Placebo
38 Suspended A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
Conditions: Nonalcoholic Steatohepatitis;   Type 2 Diabetes Mellitus
Interventions: Drug: TEV-45478;   Drug: Placebo
39 Completed
Has Results
Role of Exenatide in NASH-a Pilot Study
Conditions: Nonalcoholic Fatty Liver Disease;   (NAFLD)
Intervention: Drug: Exenatide
40 Recruiting Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Conditions: Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: AZ compound;   Other: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.